See more : OXE Marine AB (publ) (CMMCF) Income Statement Analysis – Financial Results
Complete financial analysis of Entera Bio Ltd. (ENTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entera Bio Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Vinx Corp. (3784.T) Income Statement Analysis – Financial Results
- Bank Hapoalim B.M. (BKHYY) Income Statement Analysis – Financial Results
- Hellenic Exchanges – Athens Stock Exchange S.A. (HEHSF) Income Statement Analysis – Financial Results
- FL Entertainment N.V. (FLE.AS) Income Statement Analysis – Financial Results
- Chiyoda Corporation (CHYCF) Income Statement Analysis – Financial Results
Entera Bio Ltd. (ENTX)
About Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 134.00K | 571.00K | 365.00K | 236.00K | 500.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 56.00K | 101.00K | 373.00K | 209.00K | 210.00K | 0.00 | 43.00K | 35.00K | 28.00K |
| Gross Profit | -56.00K | 33.00K | 198.00K | 156.00K | 26.00K | 500.00K | -43.00K | -35.00K | -28.00K |
| Gross Profit Ratio | 0.00% | 24.63% | 34.68% | 42.74% | 11.02% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.51M | 5.85M | 6.77M | 6.40M | 7.20M | 8.52M | 2.77M | 2.65M | 2.12M |
| General & Administrative | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Other Expenses | 0.00 | -51.00K | -46.00K | 1.24M | 743.00K | 523.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.86M | 13.05M | 12.42M | 11.29M | 11.48M | 11.36M | 11.34M | 5.37M | 3.70M |
| Cost & Expenses | 8.86M | 13.15M | 12.79M | 11.50M | 11.69M | 11.36M | 11.34M | 5.37M | 3.70M |
| Interest Income | 31.00K | 83.00K | 0.00 | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 29.00K | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 56.00K | 64.00K | 53.00K | 63.00K | 238.00K | 54.00K | 43.00K | 35.00K | 28.00K |
| EBITDA | -8.80M | -12.87M | -12.16M | -11.11M | -11.35M | -10.81M | -11.05M | -5.33M | -3.67M |
| EBITDA Ratio | 0.00% | -9,714.18% | -2,130.30% | -3,050.14% | -4,752.54% | -2,161.40% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -13.02M | -12.22M | -11.13M | -11.45M | -10.86M | 11.34M | -5.37M | -3.70M |
| Operating Income Ratio | 0.00% | -9,714.18% | -2,139.58% | -3,050.14% | -4,853.39% | -2,172.20% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.00K | 134.00K | -29.00K | -28.00K | 659.00K | 557.00K | 146.00K | 4.17M | -581.00K |
| Income Before Tax | -8.86M | -12.93M | -12.25M | -9.96M | -10.80M | -10.30M | -11.20M | -1.20M | -4.28M |
| Income Before Tax Ratio | 0.00% | -9,652.24% | -2,144.66% | -2,729.59% | -4,574.15% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 29.00K | 137.00K | -59.00K | 20.00K | 84.00K | 557.00K | -146.00K | 0.00 | 0.00 |
| Net Income | -8.89M | -13.07M | -12.19M | -9.98M | -10.88M | -10.30M | -11.20M | -1.20M | -4.28M |
| Net Income Ratio | 0.00% | -9,754.48% | -2,134.33% | -2,735.07% | -4,609.75% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.30 | -1.31 | -0.14 | -0.36 |
| EPS Diluted | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.29 | -0.94 | -0.10 | -0.36 |
| Weighted Avg Shares Out | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.96M | 8.57M | 8.57M | 11.90M |
| Weighted Avg Shares Out (Dil) | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.98M | 11.90M | 11.90M | 11.90M |
Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March...
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2...
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December...
Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
JERUSALEM, March 04, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March...
Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
JERUSALEM, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at...
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
JERUSALEM, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 27, 2023, it received an extension of 180...
Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
JERUSALEM, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that, on December 22, 2023, it closed a private placement with...
Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform
JERUSALEM, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reported today interim data from an ongoing Phase 1 study designed to...
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins, today reported corporate updates and financial results for the third quarter...
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
JERUSALEM, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, reports today that the American Society for Bone and Mineral Research (ASBMR)...
Source: https://incomestatements.info
Category: Stock Reports